Follow this blog:
RSS

World first: The dengue vaccine that eradicates multiple strains

By | July 26, 2012, 12:00 PM PDT

A new type of vaccine, the first developed to combat dengue fever, has been able to protect individuals against three of the four current viral strains.

Dengue fever, also known as breakbone fever, is an infectious tropical disease caused by the dengue virus, which is transmitted through several types of mosquito. The symptoms include fever, a rash, headache, muscle and joint pains. This later develops into dengue hemorrhagic fever, a life-threatening condition that results in bleeding, blood plasma leakage, and shock when blood pressure drops to dangerous levels.

The only ways to treat the disease are oral or intravenous rehydration and blood transfusion. However, the new vaccine — developed by French drugmaker Sanofi SA — has shown positive results in a Thai clinical trial.

Sanofi’s vaccine generated an antibody response for all four dengue virus types, but only protected against three of the four, which are all in circulation around Thailand. The company’s researchers are currently completing additional studies to try and discover why it was not as successful in the third strain.

“It’s a surprise,” company spokesman Pascal Barollier told the publication.

“We need to get to the bottom of the data to find out why it is reacting this way and wait for ongoing Phase III trials to see if it is linked to some specific situation in Thailand.”

The Phase II study involved over 4000 Thai children aged between four and eleven years old. It was conducted during an epidemic of the disease, which may be linked to why the fourth strain’s protection was not as successful.

Other companies are also working on a viable dengue shot, but the French drugmaker’s is several years ahead in development and trial status. As there is a current lack of protection against the fourth strain, a commercial launch is likely to be delayed from an expected 2014 release. Instead, it is likely to be launched in 2015, after Phase III trial data has been collected.

Most patents survive contracting the disease, but according to World Health Organisation estimates, it still kills 20,000 people per year — and most fatalities are children.

(via Reuters)

Image credit: Flickr

Start your week smarter with our weekly e-mail newsletter. It's your cheat sheet for good ideas. Get it.

Charlie Osborne

About Charlie Osborne

Charlie Osborne is a contributing editor for SmartPlanet.

Charlie Osborne

Charlie Osborne

Contributing Editor

Charlie Osborne is a freelance journalist and graphic designer based in London. In addition to SmartPlanet, she also writes the iGeneration column for business technology website ZDNet. She holds degrees in medical anthropology from the University of Kent.

Follow her on Twitter.

Charlie Osborne

Charlie Osborne

Charlie Osborne does not have financial holdings that would influence how or what she covers.

She writes for SmartPlanet and is not an employee of CBS.

If you liked this, don't miss...
1
Comments

Join the conversation!

Follow via:
RSS
0 Votes
+ -
3 out of 4 is still useful
Dengue is much worse when you catch it again, with a different strain than the first time. Your immune system thinks it has the answer but it doesn't. The virus proliferates for a long time before the immune system realizes the mistake. So a vaccine for 3 out of the 4 strains would still be very helpful in preventing the worst cases.
Posted by dmm99
6th Aug
Join the conversation
Formatting +
BB Codes - Note: HTML is not supported in forums
  • [b] Bold [/b]
  • [i] Italic [/i]
  • [u] Underline [/u]
  • [s] Strikethrough [/s]
  • [q] "Quote" [/q]
  • [ol][*] 1. Ordered List [/ol]
  • [ul][*] · Unordered List [/ul]
  • [pre] Preformat [/pre]
  • [quote] "Blockquote" [/quote]

Join the SmartPlanet community and join the conversation! Signing up is fast and free. Don't wait -- we want to hear your opinion!